Akita-Based UMN Pharma Uses Insects Cells And Shortens Flu Vaccine Production Timeline
This article was originally published in PharmAsia News
Executive Summary
Akita, Japan-based biopharmaceutical company UMN Pharma announced May 26 Japan's Pharmaceuticals and Medical Device Agency cleared the vaccine for clinical trials, and UMN plans to start the H5N1 flu vaccine trials on 125 men in June. Unlike other vaccines, UMN uses insects cells to culture the virus DNA. The process enables the company to shorten production time from currently half a year to two months. (Click here for more - Japanese language
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.